OrbiMed Advisors sells $2.83 million in Disc Medicine stock

OrbiMed Advisors LLC, a significant stakeholder in Disc Medicine, Inc. (NASDAQ:IRON), has reported selling a substantial portion of its holdings in the company. According to a recent SEC filing, OrbiMed Advisors disposed of shares totaling approximately $2.83 million. The transactions were conducted over several days, with share prices ranging between $54.00 and $54.02. The stock, currently trading at $52.24, has shown significant volatility with a beta of 2.85, according to InvestingPro data.

The transactions involved various entities affiliated with OrbiMed Advisors, including OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC, and OrbiMed Genesis GP LLC. These entities collectively reported multiple sales of Disc Medicine’s common stock, reflecting the ongoing adjustments in their investment portfolio. The company, with a market capitalization of $1.82 billion, maintains a strong balance sheet with more cash than debt and an impressive current ratio of 21.17.

The sales were executed on March 19, 20, and 21, 2025, reducing the total number of shares held by these entities. The transactions are part of routine portfolio management activities by OrbiMed Advisors, which is known for its investments in the healthcare and life sciences sectors. For deeper insights into IRON’s valuation and growth prospects, including analyst price targets ranging from $75 to $132, check out the comprehensive research available on InvestingPro.

OrbiMed Advisors, based in New York, is a prominent investment firm specializing in the healthcare sector. The firm, along with its affiliates, continues to hold a significant interest in Disc Medicine, a company focused on developing treatments for hematologic diseases. According to InvestingPro’s Financial Health assessment, the company maintains a FAIR overall rating.

In other recent news, Disc Medicine has been the focus of multiple analyst updates. Cantor Fitzgerald maintained an Overweight rating on the company, keeping its price target at $99, following an update to their financial model that reflects recent share count changes and operating expense projections. Scotiabank (TSX:BNS) raised its price target for Disc Medicine to $75, citing plans for a New Drug Application (NDA) for bitopertin in treating erythropoietic protoporphyria (EPP) by the second half of 2025. Scotiabank also noted the company’s strengthened financial position after a capital raise. TD Cowen initiated coverage with a Buy rating, highlighting Disc Medicine’s promising pipeline, including the potential of bitopertin and the underappreciated value of treatment 0974 in myelofibrosis anemia. Furthermore, Stifel increased its price target to $94, maintaining a Buy rating, following the company’s authorization to submit an NDA for bitopertin’s accelerated approval. Stifel expressed confidence in bitopertin’s approval prospects and its potential commercial launch in 2026. These developments reflect a positive outlook from analysts on Disc Medicine’s future performance and strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.